Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary presents a mixed outlook. While there are positive aspects like potential working capital release from excess inventory and optimistic production targets, there are also challenges such as farmer affordability issues and high sulfur prices impacting margins. The Q&A indicates management's optimism but also highlights uncertainties, particularly in pricing and cost management. Overall, the sentiment is balanced with both positive and negative factors, leading to a neutral stock price prediction.
Phosphate Fertilizer Production Produced 1.7 million tonnes in Q4 2025, despite an extended turnaround at the Bartow facility and deliberate production adjustments due to soft U.S. demand. Production is expected to reach at least 7 million tonnes in 2026.
Potash Production Produced around 9 million tonnes in 2025, with expectations to maintain similar levels in 2026. Esterhazy operations are back at full rates after a fatality in December, and the HydroFloat project is ramping up.
Cash Cost of Conversion (Phosphate) Improved to $112 per tonne in Q4 2025, a $20 per tonne improvement compared to earlier in the year. This improvement is structural and not one-off.
Cash Cost of Production (Potash) Averaged $75 per tonne in 2025, though higher costs were incurred due to the extension of Colonsay.
Blended Rock Cost per Tonne (Mosaic Fertilizantes) Reached $97 in 2025, the lowest level since 2021.
Cost Savings Achieved $150 million in cost savings ahead of schedule in 2025.
Net Sales (Mosaic Biosciences) Doubled to $68 million in 2025, with stable gross margins in the 40% range.
Working Capital Impact on Cash Flow Reduced cash flow by $960 million in 2025, contributing to an $829 million increase in net debt.
Sulfur Price Impact Every $10 increase in sulfur prices adds approximately $10 million of quarterly expense. A $250 million headwind to Q1 2026 EBITDA is expected due to sulfur price increases.
Excess Inventory (Phosphates) Exited 2025 with 240,000 tonnes of excess inventory, representing roughly $140 million of potential working capital release over the next few quarters.
Mosaic Biosciences: Launched five new products in 2025 and expanded commercialization in the Americas, China, and India. Achieved 60+ registrations and sales in 16 countries. Doubled net sales to $68 million in 2025. Plans to launch 8-10 new products in 2026, aiming to double net sales again.
Market Access: Expanded Brazil distribution capacity with a 1 million tonne blending facility in Palmeirante, Northern Brazil. This positions the company to meet rising demand as credit conditions normalize.
Market Share: Despite a decline in overall North America potash and phosphate shipments in 2025, Mosaic's North America sales volumes were more resilient, indicating additional market share capture.
Phosphate Production: Improved phosphate production performance in 2025, with Florida reaching its highest level in three years and record mining production at Miski Mayo. Produced 1.7 million tonnes in Q4 2025 and expects to produce at least 7 million tonnes in 2026.
Potash Production: Achieved consistently good potash production in 2025 and expects record production at Esterhazy in 2026. Plans to produce around 9 million tonnes of potash in 2026.
Cost Management: Achieved $150 million cost savings in 2025 ahead of schedule. Improved cash cost of phosphate conversion by $20 per tonne in Q4 2025. Potash production costs averaged $75 per tonne in 2025. Plans to deliver another $100 million in savings in 2026.
Asset Divestitures: Divested non-core assets, including Patos de Minas, Taquari, and a pending Carlsbad transaction, generating $170 million in proceeds and reducing $60 million in asset retirement obligations.
Capital Allocation: Plans to invest $1.5 billion in capital expenditures in 2026, focusing on mine and infrastructure expansions in Florida. Expects capital expenditures to trend down to $1 billion by 2030.
Phosphate Demand Challenges: U.S. phosphate demand fell sharply in Q4 2025 due to affordability challenges and uncertainties surrounding government support. This could strain logistics capabilities during a compressed demand timeframe in 2026.
Sulfur Price Volatility: A sharp increase in sulfur prices at the end of 2025 is expected to significantly compress margins in the Phosphate and Mosaic Fertilizantes segments well into the first half of 2026.
Brazil Operations: Credit constraints in Brazil remain a challenge, leading to the idling of Araxa and Fospar, the company's lowest-margin operations, until further notice.
Working Capital and Cash Flow Constraints: Inventory builds in finished products and raw materials in 2025 reduced cash flow by $960 million, contributing to an $829 million increase in net debt. This has constrained near-term cash flow and impacted debt management plans.
Production Recovery Delays: The recovery of production volumes in the U.S. Phosphate business has taken longer than expected, impacting operational stability and cost normalization efforts.
Environmental and Capital Expenditures: Capital expenditures are expected to rise in 2026 due to mine, gyp stack, and clay settling area expansions in Florida, increasing financial pressure.
Phosphate Production: Mosaic expects to produce at least 7 million tonnes of phosphate in 2026, with consistently good production levels anticipated.
Potash Production: The company anticipates record production at Esterhazy in 2026 and expects to produce around 9 million tonnes of potash, similar to 2025 levels.
Global Potash Shipments: Global potash shipments are expected to approach record levels in 2026, driven by broad-based demand across key geographies.
Brazilian Fertilizer Demand: Expanding planted acreage and rising crop yields are expected to support long-term fertilizer demand in Brazil, despite current credit constraints.
Mosaic Biosciences Growth: Mosaic Biosciences expects to double net sales again in 2026, driven by continued adoption of its current portfolio and 8 to 10 new product launches.
Cost Savings Initiatives: The company aims to deliver another $100 million in savings in 2026 through technology-enabled initiatives and operational efficiencies.
Capital Expenditures: CapEx is projected to be around $1.5 billion in 2026, higher than 2025, due to mine, gyp stack, and clay settling area expansions in Florida. However, CapEx is expected to trend down to approximately $1 billion by 2030.
Asset Retirement Obligations (ARO) and Environmental Reserves: Cash spending on ARO and environmental reserves is expected to decline by roughly $50 million in 2026 and trend down to about $200 million by 2030.
Working Capital and Cash Flow: A $300 million to $500 million working capital release is anticipated in 2026, supporting higher cash flow generation. EBITDA to cash flow conversion is expected to improve significantly from 2025 levels.
Phosphate Margins: Margins in the Phosphate and Mosaic Fertilizantes segments are expected to remain compressed in the first half of 2026 due to high sulfur prices.
Minimum Dividend: The company expects to generate free cash flow after CapEx and other cash spend above the minimum dividend in 2026.
Extraordinary Returns to Shareholders: The company plans to prioritize debt reduction and subsequently pave the way to resume extraordinary returns to shareholders.
The earnings call summary presents a mixed outlook. While there are positive aspects like potential working capital release from excess inventory and optimistic production targets, there are also challenges such as farmer affordability issues and high sulfur prices impacting margins. The Q&A indicates management's optimism but also highlights uncertainties, particularly in pricing and cost management. Overall, the sentiment is balanced with both positive and negative factors, leading to a neutral stock price prediction.
The earnings call shows strong demand and stable prices in phosphate and potash markets, with positive EBITDA expectations. However, concerns over workforce turnover, institutional knowledge gaps, and potential demand deferral in Q4 phosphate sales create uncertainties. Despite operational improvements and cost reduction plans, the unclear management responses in the Q&A section add to the mixed sentiment. The neutral rating reflects these balancing positive and negative factors.
Despite some positive aspects like improved production in August and strong performance in Biosciences, there are concerns over extraordinary phosphate costs and unclear responses regarding cost ramp-down. Positive factors like increased potash production and potential Q3 EBITDA growth are balanced by these uncertainties, leading to a neutral sentiment. The lack of specific guidance on certain issues and the market's negative reaction to extraordinary expenses add to the mixed outlook.
The earnings call presents a mixed picture: strong phosphate and potash prices and optimistic production outlooks are offset by supply chain challenges, higher production costs, and constrained free cash flow. The Q&A session reveals some optimism but also vagueness in responses about cost impacts and cash flow, which may concern investors. The lack of significant positive catalysts or new partnerships tempers expectations, suggesting a neutral stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.